poorly appreciated the professional performance of pharmacists. Therefore, raising the awareness about the important role of pharmacist in providing public health is warranted.

PHS119

PROFILE OF PATIENTS USING IMMUNOLOGICAL IN A HEALTH PLAN

OBJECTIVES: To assess the prevalence and control costs. METHODS: A cross-sectional concurrent study in two hospitals accredited service provider, from March to November/2012. Data were recorded by medical expertise in computerized management system (Sabius®) performed after the medical consultation. Later, these were entered in Microsoft Excel 2007 and analyzed by pharmacists auditors. The cost was calculated from the value contained in Brasinde Index 765, using the Consumer Price Max. The doses used for rheumatoid arthritis Etanercept 50 mg, 40 mg Adalimumab, abatacept 750 mg, 300 mg Infliximab, 560 mg Tocilizumab, Rituximab 1 mg and Golimumab 50 mg based on a 70 kg adult. RESULTS: We analyzed 64 patients with a mean weight 67 kg, of which 70.31% (n = 45) were women aged 30-59 years whose most frequent indications were rheumatoid arthritis (n = 33, 51.56%) and ankylosing spondylitis (n = 19, 29.69%). The most immunobiologically commonly prescribed was infliximab (n = 36; 56.25%), Tocilizimab (n = 11, 17.19%), abatacept, and rituximab (n = 9; 14.06%) and golimumab (n = 1, 1.56%). It was observed that of the patients who were immunobiologically naïve at admission (n = 21) initiated with anti-TNF, whereas 61.9% (n = 13) moved into one another with immunobiological mechanism of action and 38.1% (n = 8) continued with an anti-TNF, changing only the drug. The average cost of treatment/doe first line was R$ 1,526.00. The total cost recorded was R$ 2,011,06, resulting in an annual cost/dose of R$ 3,521.16 (36.72%). CONCLUSIONS: Knowledge of costs and pharmacotherapeutic profile becomes important for planning strategies aimed at standardization and optimization of these drugs on quality of care.

PHS120

MEDICAL RE-ADMISSIONS AT THE ROYAL LONDON HOSPITAL - PATIENT SPECIFIC AND DISEASE SPECIFIC FACTORS AT ONE WEEK AND ONE MONTH


Royal London Hospital NHS Trust, London, UK

OBJECTIVES: The Royal London Hospital is a teaching hospital in East London, UK. We hypothesised that medical patients with multiple co-morbidities and complex disease are likely to present with a new diagnosis when re-admitted within a month. Further, re-admission within a week is likely to be related to the initial diagnosis. METHODS: We conducted a retrospective audit of all non-elective adult acute medical admissions over a 6 week period during 2012. We collected information on patient demographics, ICD-10 diagnosis, length of hospital stay, along with readmissions within one week and one month. We reviewed the original and subsequent electronic discharge summaries. We highlight patient specific and disease specific factors. RESULTS: There were a total of 124 readmissions from the original audit (n=859). A large proportion (40%) of all readmissions were in the elderly (≥65). There were 73 (59%) readmissions within 1 month, and 37 (30%) within a week. Fourteen patients (11%) were readmitted within a week, and again within a month. COPD (33%), PE (29%), and polypharmacy (24%) had the highest re-admission rates. Our audit points to a 14.4% readmission rate in our cohort. We aim to address the precipitating factors in our new physician led ambulatory care clinic. We highlight patient specific factors through a cohort of patients who met the inclusion criteria. Conclusions: Medical readmissions are a complex phenomenon, which might require holistic approach to prevent readmissions. Despite the high readmission rate, interestingly this was less so when re-admitted within a week. Our audit has helped highlight the need for better community management plans prior to discharge. This has led to closer links with the Community Rehabilitation and Support Team (CReST) in order to reduce readmission rates.

PHS121

DO PATIENTS NEED TO BE ACCOMPANIED IN ICU WARDS?

Zhang Y, Zhang HY, Qiao Y

General Hospital of Liaoning Military Region, Shenyang, China; Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China

OBJECTIVES: For treatment needs, accompaniment is limited for ICU patients. A 30-minute visit a day is allowed for their families. However, mental disturbance have been reported in ICU. Actually, patients suffer from not only diseases but also loneliness in the units. The study was conducted to answer the question whether ICU patients need to be accompanied? METHODS: A questionnaire survey was conducted in the hospital to answer the question about the accompany to accommodation. We was conducted in General Hospital of Shenyang Military Area in China. The 3 questions are: 1) Do you need an companion when treated in ICU? (Yes/No); 2) If needed, who will be the candidate? (A family member/A paid nursing staff/A relative or friend/Anyone available); 3) How long do you need to stay with your accompanies? (A half-day/One half/8 hours/12 hours/24 hours). After repetability test, the questionnaire was filled by patients randomly selected in the Neutronics and geriatric wards from January 1 to August 31, 2011. Chi-square tests were used to compare the choices between patients from different wards, of different gender and age. RESULTS: repeatabilities for the 3 questions were 0.742, 0.783, and 0.785. Totally, 142 patients were involved in, including 69 ICU patients and 73 general patients, 117 males and 25 females, 53 young & middle aged (≥60 years old) and 89 old ones (>60). Fifty-seven percent of the patients needed accompanies in ICU, 86.6% of the patients chose family members as the candidates, 74.6% of the patients needed all-day accompany by family members. In case of patients needing half-day and all-day accompany by family members were higher in ICU and old patients than those in general and younger ones (p<0.05). CONCLUSIONS: Patients do need to be accompanied in ICU. At all-day accompany by family member is highly preferred.

PHS122

FIT FALLS OF THE NATIONAL HEALTH SERVICE (NHS) "INTERNAL MARKET" HEALTH CARE MODEL; DOES REIMBURSEMENT OF SECONDARY CARE MATCH COSTS INCURRED

Royal London Hospital NHS Trust, London, UK

OBJECTIVES: Many NHS hospitals have developed an Acute Medicine Unit to streamline all non-elective medical admissions. The cost of providing this secondary care service is funded by the local primary care team, who in turn receive funding from central government. However, teaching hospitals in the capitol would also care for a considerable number of international and national patients. We sought to examine if health care costs were reimbursed for these patients. METHODS: We undertook a retrospective audit of all admissions over a 6 week period at a central London teaching hospital. We collected patient demographics, ICD-10 diagnosis and length of stay. We identified all “out of area” patients and calculated costs incurred based on bed days, diagnosis and readmission within a month. The ICD-10 codes were converted to cost (HRG) codes through the finance office. RESULTS: A total of 864 admissions and 124 readmissions were analysed. In all 28% (n=243) of admissions were “out of area.” This cohort accounted for 25% of bed occupancy, and cost the hospital £390,300. Further, 1% (n=8) of patients were of no fixed abode (homeless) and cost £7,200 in bed occupancy. The international patients account for 1% (n=6) and cost £4,500 in bed occupancy. The top 3 presenting complaints with disease management costs were, Sickle cell anaemia (n=27-€34,899) chest pain (n=24-€16,757) and lower respiratory tract infection (n=19-€69,288). We went on to compare the income generated from these admissions on an individual basis. Initial analysis pointed to a deficit in income generated. This has significant implications for the financial viability of secondary/tertiary care hospitals in the NHS. CONCLUSIONS: Our analysis point to a considerable financial burden from “out of area” patients to the hospital. Reducing this financial burden does raise clinical and ethical challenges to the receiving hospital.

PHS123

THE EFFECT OF COPAYMENTS FOR PRESCRIPTIONS ON ADHERENCE TO MEDICINES IN PUBLICLY INSURED POPULATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Long L, Buckley C, O’Riordan D, Bradley C, Whelton H

University College Cork, Cork, Ireland

OBJECTIVES: To quantitatively estimate the effect of copayments for prescriptions on adherence to medicines in a publicly insured population. METHODS: Eight electronic databases and the grey literature were systematically searched by one reviewer for relevant articles, along with hand searches of references in review articles and the included studies. Studies were included if they examined a publicly funded health system. The analysis was limited to patients with a publicly funded health system who were prescribed medicines for chronic conditions. Rates of adherence were estimated from studies that met the inclusion criteria. Five studies contributed more than 1 result to the meta-analysis. The meta-analysis included 199,996 people overall; 74,236 people in the copayment group, and 125,760 people in the non-copayment group. RESULTS: Average age was 71.75 years. In the copayment group, (versus the non-copayment group), the odds ratio for non-adherence was 1.11 (95% CI 1.09-1.14; P<0.001). An acceptable level of heterogeneity at I²=10%, (p=0.65) was observed. CONCLUSIONS: This meta-analysis showed an 11% increased odds of non-adherence to medicines in publicly insured populations involved in a system where copayments for medicines are necessary. Policy-makers should be wary of potential negative impacts associated with lack of adherence. Unintended economic repercussions of copayments are possible.

PHS124

REIMBURSEMENT LANDSCAPE AND POLICY DEVELOPMENT FOR RARE DISEASES IN CHINA: A CASE STUDY OF HEMOPHILIA


Shanghai Medical College, Shanghai, China

OBJECTIVES: Hemophilia, a costly yet treatable rare disease, receives 100% reimbursement coverage in most developed world and some developing countries. However, in China, a P-potential negative impact. People are at high risk of non-adherence. The need of secondary/tertiary care (including hemophilia) should be prioritized to ease patients’ economic burdens. This study aims to understand the current reimbursement landscape for hemophilia in China and to explore potential funding mechanisms that could be undertaken. This study examines the existing reimbursement landscape for hemophilia in China with the aim of understanding the potential landscape for future development. METHODS: Hemophilia reimbursement policies of 3 major social insurance schemes were collected in 36 cities (provincial capitals and municipalities). In-depth interviews were conducted with selected government stakeholders to understand the rationale of different policies in different cities.
and implementation results. RESULTS: Outpatient hemophilia treatment is covered by health insurance schemes in more than 80% of the selected cities, yet with reimbursement caps and patient co-pay requirements. There is a significant variation in the payment requirement; more than 50% and annual reimbursement is usually capped below USD16k (100k CNY). However, some cities have pioneered innovative policies to provide better coverage for hemophilia patients: Guangzhou health insurance bureau has decreased hemophilia co-payments to less than 10% after their extensive review of the economics of hemophilia treatment. The local health insurance bureau in Qingdao has decided to joint-fund prophylaxis treatment for pediatric patients together with a FVIII manufacturer. CONCLUSIONS: Hemophilia treatment reimbursement in China is still at a low level overall despite a few pioneer cities which have identified unique approaches to reducing the economic burden of patients living with hemophilia. There is significant room to increase reimbursement ratio and cap to reduce patients' economic burden, and meanwhile we expect tailored public-private partnerships to be a promising supplementing solution.

**PHS125**

**MULTI-PAYERS COMPARISON OF DAILY REIMBURSEMENT VALUES OF DISTINCT HOSPITAL FACILITIES IN THE BRAZILIAN PRIVATE HEALTH SYSTEM**

**OBJECTIVES:** In the Brazilian public health system, a business-to-business negotiation manages to reimburse the entire country for the use of different health care facilities. In the supplementary/private system, as a business-to-business negotiation, each the hospital negotiates different reimbursement values for each of the use of distinct hospital facilities. There are eight different types of hospital facilities available in the supplementary system: standard, cardiovascular unit, surgery unit, psychiatric, day hospital, nursery, adult ICN, and pediatric ICU. The objective of this research is to find out among hospital facilities daily reimbursement values and establish a mean reimbursement value for each facility type in the private health care.

**METHODS:** Data was obtained from BI2iM database, a 5 million people sample of the Brazilian supplementary health care market. All values are in 2009 Brazilian reais (US$1.00 = R$ 2.00). Data are presented as mean±standard deviation. RESULTS: 65% of the patients are from medical cooperatives, HMOs 20%, self-management 15%. A total of 303,573 hospitalizations were reviewed with a total expenditure of R$ 82.9 million. The mean reimbursement for each facility type was: standard R$ 152.43±R$ 148.80, cardiovascular unit R$ 183.03±R$ 92.63, surgery unit R$ 202.06±R$ 87.74, psychiatric R$ 121.42±R$ 50.66, day hospital R$ 79.62±R$ 23.50, nursery R$ 73.22±R$ 30.67, adult ICU R$ 625.92±R$ 305.71 and pediatric ICU R$ 762.91±R$ 330.58. CONCLUSIONS: There is not a single reimbursement list (health plans to the providers) or fixed values for hospital facilities daily reimbursement values. We found different mean values of hospital facilities daily reimbursement that vary according to the facility type. Even within the same facility type there is also reimbursement value variation.

**PHS126**

**FACTORS INFLUENCING THE VARIATION IN HOSPITAL INPATIENT PRICES BETWEEN PUBLIC AND PRIVATE PAYERS**

**OBJECTIVES:** The large variation in payments hospitals receive for similar services for public (Medicare) and private payers among different hospital services. METHODS: We extracted hospital data from six states where a Healthcare Cost and Utilization Project (HCUP) price-to-charge ratio (PCR) was available from the 2006 State Inpatient Databases (SID). Even in states with PCR data, the PCR was not available for Kaiser Permanente hospitals so those discharges were excluded. The price per discharge was measured at the county-level for all discharges, an acute condition (acute myocardial infarction), and an elective condition (knee arthroplasty). Payor-specific inpatient prices were estimated by applying the HCUP PCR to total hospital charges. Ordinary least squares regression models were used to identify factors significantly associated with inpatient price per discharge by payer. RESULTS: Hospitals charged significantly higher prices to private payers compared to public payers. There was more variation in price per discharge for private payers compared to public payers for most hospital services. Specific market factors, including hospital competition, were associated with the price variation between payers. CONCLUSIONS: The larger variation in the price per discharge identified among private payers necessitates further exploration of differences in negotiated prices and market power across small geographic areas, or the price restraints of public payers.

**PHS127**

**IN VITRO FERTILIZATION (IVF): GLOBAL TRENDS IN MARKET DYNAMICS AND REIMBURSEMENT POLICIES**

**OBJECTIVES:** To understand the IVF policy landscape, reimbursement and access to treatment in the global health markets, and trends and drivers of change, for the purpose of identifying markets likely to support reproductive health franchises.

**METHODS:** IVF ecosystems were assessed in 19 countries. We conducted a documentary review of public and private access to reproductive technology (ART) policy, reviewed infertility organization and clinic websites and associated publications. Key market differences impacting the IVF ecosystem were identified and analyzed for each country. RESULTS: Opportunities in IVF must consider reimbursement policy, cultural influences, and med-tourism. While the US is one of the most advanced markets with respect to number of IVF cycles, technologies utilized, and cultural trends, healthcare systems provide no reimbursement and most use out-of-pocket (OOP). Elsewhere, reimbursement varies greatly: Israel and European countries tend to provide more generous reimbursement than Latin America and Africa due to more restrictive public health systems. Recent legislation changes in European markets have expanded reimbursement, and changes in South America are likely to evolve as reproductive health awareness and access to infertility treatment becomes more widespread. Finally, many patients do seek treatment abroad due to lower costs, shorter waitlists, and fewer restrictions: South America, South Africa, and Israel tend to be sought after destinations for patients willing to pay OOP. CONCLUSIONS: Reproductive health is unlike other therapeutic areas because reimbursement, alone, is insufficient to assess opportunity. Given the breadth of this poorly reimbursed therapeutic area, stakeholders must seek to appreciate the impact of cultural trends and med-tourism, including declining birth rates, increasing access to IVF, and generational health care decisions. Key factors to consider include: access to IVF reimbursement; market size – and growth; choice of technologies; competition; and reforms to public policy. Manufacturers and policy makers should prepare to understand evolving market access and patient environments to effectively navigate traditionally overlooked countries as key factors shift in the coming years.